The FDA Approves AI Tools for Breast Cancer Risk Assessment

The U.S. Food and Drug Administration (FDA) has given the green light to two new shots, happening only once a year, aimed at preventing HIV, as announced by Gilead Sciences on Wednesday.

The injectable medication, known as Lenacapavir and marketed under the name Yeztugo, significantly lowers the risk of sexually transmitted HIV in both adults and adolescents.

“Today marks a historic moment in the ongoing battle against HIV,” stated Gilead’s CEO Daniel O’Day in a press release.

In other related findings, it appears that certain antiviral drugs already available may offer protective benefits against Alzheimer’s disease. These medications, which require management just twice a year, reportedly show impressive results. According to Gilead, this could revolutionize HIV prevention.

Administered as an under-the-skin injection, this drug is absorbed gradually by the body. Before starting treatment, it’s essential for individuals to have a negative HIV-1 test.

A substantial trial last year demonstrated that Lenacapavir is almost 100% effective in preventing HIV and outperforming daily oral options like Truvada, another Gilead product.

Interestingly, Science Journal named Lenacapavir as the “Breakthrough of the Year” for 2024, emphasizing its innovative multi-stage approach that sets it apart from other approved antiviral drugs.

While many antiviral medications typically act in just one stage of viral replication, Lenacapavir targets multiple stages throughout the virus’s life cycle, according to Gilead.

“Yeztugo represents one of the most significant scientific advancements of our time and presents a tangible opportunity to help eliminate the HIV epidemic,” O’Day mentioned in the press release.

As with any medication, the most frequently reported side effects during clinical trials included reactions at the injection site, headaches, and nausea.